Pulmonx Q3 2026 Results: Revenue Up, Losses Persist Amid Heavy R&D Spending
Pulmonx’s Q3 2026 results show modest revenue growth but ongoing R&D‑heavy losses, with $53M cash and a $38M debt load; yet the company remains focused on innovative pulmonary devices and a positive 12‑month outlook.
2 minutes to read